Lin Wei, Feng Meng, Liu Tingting, Wang Qingxu, Wang Wenqi, Xie Xiao, Li Wenhao, Guan Jitian, Ma Zhongyu, Liu Tong, Zhou Qingjun
School of Basic Medicine, Shandong First Medical University and Shandong Academy of Medical Science, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Jinan, China.
Front Med (Lausanne). 2022 Mar 22;9:797087. doi: 10.3389/fmed.2022.797087. eCollection 2022.
To investigate the intravitreal injection of conbercept as a treatment strategy for proliferative diabetic retinopathy (PDR) with or without center-involved diabetic macular edema (CI-DME) and evaluate its effect on the microvascular changes in the eyes.
In this prospective study, 43 patients including 29 cases (56 eyes) in CI-DME with PDR patients, and 14 cases (26 eyes) in the non-center involving diabetic macular edema (NCI-DME) with PDR patients were involved in this study. The best corrected visual acuity (BCVA), central retinal thickness (CRT), foveolar avascular zone (FAZ), and macular capillary vessel density (VD) of the superficial retinal capillary plexus (SCP) and deep retinal capillary plexus (DCP) were assessed before and after conbercept treatments for 1, 3, or 6 months.
The BCVA was significantly increased after conbercept treatment in the eyes of CI-DME patients. After 6 months of treatment with the conbercept, microvascular density of the inferior area in SCP and the central fovea area in DCP increased significantly, regardless of the central fovea involvement. The effect of the conbercept treatment on the VD of NCI-DME was higher than that of CI-DME. Then, after 6 months of treatment, the CRT of patients with CI-DME and NCI-DME were decreased significantly.
In this study, an intravitreal injection of conbercept significantly improved vision, alleviated macular edema in patients with DME. Conbercept treatment also altered the microvascular density in the retina.
探讨玻璃体内注射康柏西普作为增殖性糖尿病视网膜病变（PDR）伴或不伴累及中心的糖尿病性黄斑水肿（CI-DME）的治疗策略，并评估其对眼部微血管变化的影响。
在这项前瞻性研究中，纳入了43例患者，其中包括29例（56只眼）患有PDR的CI-DME患者和14例（26只眼）患有PDR的非累及中心的糖尿病性黄斑水肿（NCI-DME）患者。在康柏西普治疗1、3或6个月前后，评估最佳矫正视力（BCVA）、中心视网膜厚度（CRT）、黄斑无血管区（FAZ）以及浅表视网膜毛细血管丛（SCP）和深部视网膜毛细血管丛（DCP）的黄斑毛细血管血管密度（VD）。
CI-DME患者眼内注射康柏西普后BCVA显著提高。康柏西普治疗6个月后，无论黄斑中心凹是否受累，SCP下方区域和DCP中心凹区域的微血管密度均显著增加。康柏西普治疗对NCI-DME的VD的影响高于CI-DME。然后，治疗6个月后，CI-DME和NCI-DME患者的CRT均显著降低。
在本研究中，玻璃体内注射康柏西普显著改善了视力，减轻了DME患者的黄斑水肿。康柏西普治疗还改变了视网膜中的微血管密度。
